Research
Daily, oral GLP-1 medication reduced episodes of sleep apnea in adults with excess weight
The Brief
- In a trial, adults with moderate-to-severe sleep apnea and excess weight had significantly fewer breathing-interruption episodes during sleep after one year of a daily oral GLP-1 medication, orforglipron.
- The comparison group was adults taking a placebo, according to the reported results.
Why it matters
The results suggest an oral GLP-1 drug may reduce sleep apnea episodes in people with excess weight, which could matter for future treatment options; readers should weigh these findings as those of a single reported study.
Who’s affected
- clinicians treating sleep apnea and obesity
- adults with excess weight and moderate-to-severe sleep apnea
- #sleep apnea
- #glp-1
- #obesity
- #clinical trial
- #orforglipron
Adults with moderate-to-severe sleep apnea and excess weight had significantly fewer episodes of breathing interruptions while sleeping after taking the daily oral GLP-1 medication orforglipron for one year, compared with adults in the placebo group, according to new…